{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:47:50Z","timestamp":1789717670333,"version":"4.0.1"},"reference-count":197,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":611,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1124\/dmd.122.001131","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T20:00:27Z","timestamp":1675368027000},"page":"543-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Activation\/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-6277","authenticated-orcid":false,"given":"Fengling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.001131_bib1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12032-018-1146-z","article-title":"Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia","volume":"35","author":"Abumiya","year":"2018","journal-title":"Med Oncol"},{"key":"10.1124\/dmd.122.001131_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine","volume":"14","author":"Ahmed","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1124\/dmd.122.001131_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/1078-0432.CCR-07-4020","article-title":"Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study","volume":"14","author":"Albertella","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10408363.2011.599831","article-title":"Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer","volume":"48","author":"Allin","year":"2011","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1124\/dmd.122.001131_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000502097","article-title":"Tumor macroenvironment: an update","volume":"87","author":"Al-Zoughbi","year":"2020","journal-title":"Pathobiology"},{"key":"10.1124\/dmd.122.001131_bib8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.001131_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/tpj.2014.67","article-title":"High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme","volume":"15","author":"Apell\u00e1niz-Ruiz","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.122.001131_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/1078-0432.CCR-14-1758","article-title":"Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy","volume":"21","author":"Apell\u00e1niz-Ruiz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib11","first-page":"552","article-title":"Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile","volume":"6","author":"Assis","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"10.1124\/dmd.122.001131_bib12","doi-asserted-by":"crossref","first-page":"13486","DOI":"10.1038\/s41598-020-70351-0","article-title":"Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy","volume":"10","author":"Atasilp","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.122.001131_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00228-020-02828-w","article-title":"Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors","volume":"76","author":"Azam","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.122.001131_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-014-2963-1","article-title":"Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22","volume":"145","author":"Baxter","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/dmd.122.001131_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/bdd.411","article-title":"Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A","volume":"25","author":"Bekaii-Saab","year":"2004","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.122.001131_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1055-9965.EPI-19-0449","article-title":"Expression patterns of xenobiotic-metabolizing enzymes in tumor and adjacent normal mucosa tissues among patients with colorectal cancer: the ColoCare Study","volume":"29","author":"Beyerle","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/dmd.122.001131_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-018-0719-5","article-title":"Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients","volume":"58","author":"Bins","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.119.088823","article-title":"Interindividual variation in CYP3A activity influences lapatinib bioactivation","volume":"47","author":"Bissada","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1124\/dmd.113.052316","article-title":"Comparison of endogenous 4\u03b2-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin","volume":"41","author":"Bj\u00f6rkhem-Bergman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib21","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1021\/jm0607449","article-title":"Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma","volume":"49","author":"Boyer","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001131_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11095-018-2458-6","article-title":"Characterization of intestinal and hepatic CYP3A-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach","volume":"35","author":"Brussee","year":"2018","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.001131_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/jhep.2001.29306","article-title":"Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts","volume":"34","author":"Chalasani","year":"2001","journal-title":"Hepatology"},{"key":"10.1124\/dmd.122.001131_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv"},{"key":"10.1124\/dmd.122.001131_bib25","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1158\/1078-0432.CCR-06-0023","article-title":"Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer","volume":"12","author":"Charles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib26","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients","volume":"12","author":"Chen","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.001131_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1289\/ehp.0800528","article-title":"Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine","volume":"117","author":"Chen","year":"2009","journal-title":"Environ Health Perspect"},{"key":"10.1124\/dmd.122.001131_bib28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3565(24)29199-0","article-title":"Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos","volume":"299","author":"Dai","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001131_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40360-020-00456-9","article-title":"The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats","volume":"21","author":"Darweesh","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1124\/dmd.122.001131_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1124\/dmd.122.001131_bib31","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-12-3786","article-title":"CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity","volume":"19","author":"de Graan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpba.2007.12.006","article-title":"Metabolism pathway of vinorelbine (Navelbine) in human: characterisation of the metabolites by HPLC-MS\/MS","volume":"47","author":"de Graeve","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.122.001131_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104551","article-title":"Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems","volume":"151","author":"Dehshahri","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.122.001131_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41397-021-00227-7","article-title":"Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients","volume":"21","author":"Demurtas","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.122.001131_bib35","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","article-title":"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6","volume":"310","author":"Desta","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001131_bib36","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.115.069203","article-title":"Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor","volume":"44","author":"Dickinson","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/tpj.2015.100","article-title":"Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma","volume":"17","author":"Diekstra","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.122.001131_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/clpt.2014.47","article-title":"Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662","volume":"96","author":"Diekstra","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.pharmtox.43.100901.140251","article-title":"Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts","volume":"43","author":"Ding","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.122.001131_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cca.2007.04.027","article-title":"Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations","volume":"383","author":"Du","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1124\/dmd.122.001131_bib42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-014-1675-0","article-title":"Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin","volume":"70","author":"Dutreix","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00008571-200107000-00008","article-title":"Identification and functional characterization of eight CYP3A4 protein variants","volume":"11","author":"Eiselt","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001131_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03321.x","article-title":"Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa","volume":"67","author":"Ekhart","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/FPC.0b013e32834c6edb","article-title":"Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study","volume":"21","author":"Elens","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.122.001131_bib46","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s002800000121","article-title":"Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat","volume":"46","author":"Ewesuedo","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib47","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13318-019-00595-3","article-title":"Correlation of PPM1A downregulation with CYP3A4 repression in the tumor liver tissue of hepatocellular carcinoma patients","volume":"45","author":"Flannery","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","article-title":"Effect of St John\u2019s wort on imatinib mesylate pharmacokinetics","volume":"76","author":"Frye","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12032-014-0335-7","article-title":"Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study","volume":"32","author":"Fucile","year":"2015","journal-title":"Med Oncol"},{"key":"10.1124\/dmd.122.001131_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.9210","article-title":"Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population","volume":"23","author":"Fukushima-Uesaka","year":"2004","journal-title":"Hum Mutat"},{"key":"10.1124\/dmd.122.001131_bib52","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0022-3565(24)38249-7","article-title":"Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers","volume":"289","author":"Furlan","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001131_bib53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1067\/mcp.2002.121371","article-title":"CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity","volume":"71","author":"Garc\u00eda-Mart\u00edn","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bcp.2012.04.001","article-title":"Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites","volume":"84","author":"Ghassabian","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib55","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2217\/pgs-2019-0101","article-title":"Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma","volume":"20","author":"Goey","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.001131_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.113","article-title":"A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma","volume":"3","author":"Goldinger","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.122.001131_bib57","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10637-010-9514-3","article-title":"Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma","volume":"29","author":"Gomo","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.122.001131_bib58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/mol.62.2.359","article-title":"Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor","volume":"62","author":"Goodwin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib59","first-page":"1329","article-title":"The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module","volume":"56","author":"Goodwin","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib60","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/bcr2570","article-title":"Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study","volume":"12","author":"Gor","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00520-006-0127-5","article-title":"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions","volume":"15","author":"Haddad","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1124\/dmd.122.001131_bib62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-014-2390-3","article-title":"The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects","volume":"73","author":"Hamilton","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115000","article-title":"Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant","volume":"396","author":"Hannachi","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/dmd.113.054817","article-title":"Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells","volume":"42","author":"Hardy","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib65","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejca.2008.02.047","article-title":"Systematic review of the association between circulating interleukin-6 (IL-6) and cancer","volume":"44","author":"Heikkil\u00e4","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1124\/dmd.122.001131_bib66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/tpj.2016.60","article-title":"Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer","volume":"17","author":"Hertz","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.122.001131_bib67","first-page":"1255","article-title":"The effect of an individual\u2019s cytochrome CYP3A4 activity on docetaxel clearance","volume":"6","author":"Hirth","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib68","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcph.1926","article-title":"Pharmacokinetics of asciminib in individuals with hepatic or renal impairment","volume":"61","author":"Hoch","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib69","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1038\/s41598-020-66583-9","article-title":"Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters","volume":"10","author":"Hsieh","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.122.001131_bib70","first-page":"268","article-title":"Novel mutations of CYP3A4 in Chinese","volume":"29","author":"Hsieh","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00228-016-2108-z","article-title":"Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects","volume":"73","author":"Hsyu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/pgs-2016-0179","article-title":"Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population","volume":"18","author":"Hu","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.001131_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cccn.2004.11.005","article-title":"CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population","volume":"353","author":"Hu","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1124\/dmd.122.001131_bib74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1124\/dmd.122.001131_bib75","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib76","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3390\/ijms20143392","article-title":"Identification of human enzymes oxidizing the anti-thyroid-cancer drug vandetanib and explanation of the high efficiency of cytochrome P450 3A4 in its oxidation","volume":"20","author":"Indra","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.001131_bib77","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","article-title":"Obesity and cancer mechanisms: tumor microenvironment and inflammation","volume":"34","author":"Iyengar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.122.001131_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-002-0453-3","article-title":"Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA","volume":"49","author":"Jacobson","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib79","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.122.001131_bib80","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"10.1124\/dmd.122.001131_bib81","first-page":"4391","article-title":"Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy","volume":"58","author":"Jounaidi","year":"1998","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17425255.4.2.137","article-title":"Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing","volume":"4","author":"Kacevska","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.122.001131_bib83","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(24)15196-3","article-title":"CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes","volume":"28","author":"Kajita","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/dmd.110.032276","article-title":"In vitro cytochrome P450-mediated metabolism of exemestane","volume":"39","author":"Kamdem","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2003.08.015","article-title":"Expression of CYP3A4 in human breast tumour and non-tumour tissues","volume":"202","author":"Kapucuoglu","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1124\/dmd.122.001131_bib86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib: a review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"10.1124\/dmd.122.001131_bib87","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","article-title":"The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions","volume":"40","author":"Kivist\u00f6","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib88","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/156800911795538066","article-title":"Cytokines, inflammation and colon cancer","volume":"11","author":"Klampfer","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1124\/dmd.122.001131_bib89","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cgh.2006.12.021","article-title":"Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity","volume":"5","author":"Kolwankar","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.122.001131_bib90","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1158\/1078-0432.CCR-04-2488","article-title":"Effect of the St. John\u2019s wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures","volume":"11","author":"Komoroski","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib91","first-page":"8","article-title":"Effects of obesity on the cytochrome P450 enzyme system","volume":"37","author":"Kotlyar","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib92","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"Krens","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.122.001131_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113725","article-title":"MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation","volume":"171","author":"Kugler","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib94","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1124\/dmd.115.063610","article-title":"Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites","volume":"43","author":"Lacy","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001131_bib96","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1124\/dmd.122.001131_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.733935","article-title":"Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature","volume":"12","author":"Lenoir","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib98","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1124\/dmd.108.025932","article-title":"Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways [published correction appears in Drug Metab Dispos (2009) 37:2118 (Vojkovsky T added)]","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib99","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/tx900256y","article-title":"Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities","volume":"22","author":"Li","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.001131_bib100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ijms18030603","article-title":"Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients","volume":"18","author":"Liu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.001131_bib101","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/bph.14916","article-title":"Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: a new strategy for CYP3A-mediated drug hepatotoxicity","volume":"177","author":"Liu","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib102","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/00498254.2020.1867929","article-title":"Expression of cytochrome P450 isozyme transcripts and activities in human livers","volume":"51","author":"Liu","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001131_bib103","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2217\/pgs-2018-0095","article-title":"Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients","volume":"19","author":"Maagdenberg","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.001131_bib104","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40487-016-0035-x","article-title":"Impact of CYP3A4*18 and CYP3A5*3 polymorphisms on imatinib mesylate response among chronic myeloid leukemia patients in Malaysia","volume":"4","author":"Maddin","year":"2016","journal-title":"Oncol Ther"},{"key":"10.1124\/dmd.122.001131_bib105","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1124\/dmd.110.034140","article-title":"CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs","volume":"38","author":"Maekawa","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib106","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-017-3388-4","article-title":"Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients","volume":"80","author":"Makihara","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib107","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/j.bmc.2013.03.038","article-title":"The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588","volume":"21","author":"Manley","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.122.001131_bib108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/138920007779815986","article-title":"Transcriptional regulation and expression of CYP3A4 in hepatocytes","volume":"8","author":"Mart\u00ednez-Jim\u00e9nez","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001131_bib109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjc.6600494","article-title":"Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy","volume":"87","author":"Mart\u00ednez","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.122.001131_bib110","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/94.16.1247","article-title":"Effects of St. John\u2019s wort on irinotecan metabolism","volume":"94","author":"Mathijssen","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.122.001131_bib111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00498250400026464","article-title":"Cytochrome P450-dependent metabolism of gefitinib","volume":"35","author":"McKillop","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001131_bib112","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-12-1335","article-title":"Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors","volume":"72","author":"Mitsiades","year":"2012","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib113","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijc.1568","article-title":"Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues","volume":"97","author":"Miyoshi","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1124\/dmd.122.001131_bib114","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2018.4","article-title":"2017 FDA drug approvals","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.001131_bib116","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clpt.2006.04.012","article-title":"Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer","volume":"80","author":"Nakajima","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib117","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10637-014-0178-2","article-title":"Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients","volume":"33","author":"Narjoz","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.122.001131_bib118","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","article-title":"Inter-patient variability in docetaxel pharmacokinetics: a review","volume":"41","author":"Nieuweboer","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/dmd.122.001131_bib119","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00280-013-2187-9","article-title":"Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma","volume":"72","author":"Noda","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"10.1124\/dmd.122.001131_bib121","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01718.x","article-title":"Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function","volume":"55","author":"Orlando","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib122","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00228-018-02609-6","article-title":"Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer","volume":"75","author":"Oyaga-Iriarte","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib123","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001131_bib124","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","article-title":"Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer","volume":"9","author":"Ozeki","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.122.001131_bib125","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jcph.1430","article-title":"Pharmacokinetics of lapatinib, a nonrenally cleared drug, in patients with end-stage renal disease on maintenance hemodialysis","volume":"59","author":"Pai","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib126","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib127","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2147\/IJN.S141145","article-title":"Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel","volume":"12","author":"Paolini","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1124\/dmd.122.001131_bib128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.taap.2004.01.010","article-title":"The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes","volume":"199","author":"Parkinson","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib129","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/1078155217724863","article-title":"Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism","volume":"24","author":"Patel","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1124\/dmd.122.001131_bib130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2174\/1381612023394502","article-title":"Tumour cytochrome P450 and drug activation","volume":"8","author":"Patterson","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1124\/dmd.122.001131_bib131","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1200\/JCO.2005.06.075","article-title":"Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer","volume":"23","author":"Petros","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.122.001131_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.10.024","article-title":"Cytochrome P450s in the development of target-based anticancer drugs","volume":"259","author":"Purnapatre","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1124\/dmd.122.001131_bib133","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.1404","article-title":"Factors affecting tamoxifen metabolism in patients with breast cancer: preliminary results of the French PHACS Study","volume":"106","author":"Puszkiel","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib134","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40262-018-0703-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of dabrafenib","volume":"58","author":"Puszkiel","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib135","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/1078-0432.CCR-04-1845","article-title":"Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes","volume":"11","author":"Quintieri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib136","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283498ecf","article-title":"Genetic epidemiology of induced CYP3A4 activity","volume":"21","author":"Rahmioglu","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.122.001131_bib137","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib138","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-019-03921-3","article-title":"Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors","volume":"84","author":"Reddick","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib139","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0026-895X(25)09935-3","article-title":"O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4","volume":"45","author":"Relling","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib140","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/bcp.13574","article-title":"Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity","volume":"84","author":"Riera","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib141","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2008.11.001","article-title":"Microtubule dynamics as a target in oncology","volume":"35","author":"Risinger","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/dmd.122.001131_bib142","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","article-title":"Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response","volume":"87","author":"Rivory","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.122.001131_bib143","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","article-title":"Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.122.001131_bib144","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cca.2007.05.004","article-title":"Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects","volume":"383","author":"Ruzilawati","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1124\/dmd.122.001131_bib145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00280-007-0634-1","article-title":"Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients","volume":"62","author":"Sai","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib146","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00595-009-4328-7","article-title":"CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer","volume":"41","author":"Sakurai","year":"2011","journal-title":"Surg Today"},{"key":"10.1124\/dmd.122.001131_bib147","first-page":"2012","article-title":"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans","volume":"6","author":"Santos","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib148","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.114.060061","article-title":"Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men","volume":"43","author":"Scheers","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib149","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/01.fpc.0000182779.03180.ba","article-title":"Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations","volume":"16","author":"Schirmer","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.122.001131_bib150","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.bjc.6601492","article-title":"CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes","volume":"90","author":"Schmidt","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.122.001131_bib151","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1124\/dmd.122.001131_bib152","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00008571-199810000-00004","article-title":"Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver","volume":"8","author":"Shou","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001131_bib153","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2217\/pgs-2018-0080","article-title":"Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients","volume":"19","author":"Sim","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.122.001131_bib154","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11095-021-03019-7","article-title":"Modeling approach to predict the impact of inflammation on the pharmacokinetics of CYP2C19 and CYP3A4 substrates","volume":"38","author":"Simon","year":"2021","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.001131_bib155","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1592\/phco.24.16.1508.50958","article-title":"The influence of St. John\u2019s wort on the pharmacokinetics and protein binding of imatinib mesylate","volume":"24","author":"Smith","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.122.001131_bib156","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008571-200207000-00003","article-title":"The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer","volume":"12","author":"Spurdle","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001131_bib157","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/j.1875-9114.1997.tb03075.x","article-title":"Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure","volume":"17","author":"Stanek","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.122.001131_bib158","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/tx3000335","article-title":"Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases","volume":"25","author":"Stiborov\u00e1","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.001131_bib159","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/dmd.122.001131_bib161","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/dmd.110.037531","article-title":"Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib","volume":"39","author":"Takakusa","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib162","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0091270010367428","article-title":"Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants","volume":"51","author":"Tanaka","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib163","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","article-title":"IL-6 and related cytokines as the critical lynchpins between inflammation and cancer","volume":"26","author":"Taniguchi","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1124\/dmd.122.001131_bib164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-013-2511-4","article-title":"CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy","volume":"139","author":"Teft","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/dmd.122.001131_bib165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib","volume":"78","author":"Teng","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib166","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib167","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10549-012-1995-7","article-title":"Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence","volume":"133","author":"Teo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/dmd.122.001131_bib168","series-title":"StatPearls","article-title":"Tyrosine kinase inhibitors","author":"Thomson","year":"2021"},{"key":"10.1124\/dmd.122.001131_bib169","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2174\/1389200216666150223152627","article-title":"CYP3A4-mediated pharmacokinetic interactions in cancer therapy","volume":"15","author":"Tian","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001131_bib170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/1354750X.2020.1754913","article-title":"Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients","volume":"25","author":"Torres Esp\u00edndola","year":"2020","journal-title":"Biomarkers"},{"key":"10.1124\/dmd.122.001131_bib171","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1124\/dmd.116.070839","article-title":"Cytochrome P450 3A4 and CYP3A5-catalyzed bioactivation of lapatinib","volume":"44","author":"Towles","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib172","first-page":"178","article-title":"Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia-inducible factor 1\u03b1-mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation","volume":"41","author":"Valencia-Cervantes","year":"2019","journal-title":"Oncol Rep"},{"key":"10.1124\/dmd.122.001131_bib173","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-019-03905-3","article-title":"Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes","volume":"84","author":"van Eijk","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib174","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40262-017-0579-4","article-title":"Higher midazolam clearance in obese adolescents compared with morbidly obese adults","volume":"57","author":"van Rongen","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib175","first-page":"589","article-title":"Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors","volume":"66","author":"Villikka","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074471","article-title":"Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis","volume":"8","author":"Vuppalanchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.001131_bib177","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-020-04191-0","article-title":"An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib","volume":"87","author":"Wang","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib178","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1002\/pmic.200800144","article-title":"A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes","volume":"8","author":"Wang","year":"2008","journal-title":"Proteomics"},{"key":"10.1124\/dmd.122.001131_bib179","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.113.053793","article-title":"Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials","volume":"42","author":"Wang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001131_bib180","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib181","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.clpt.2005.11.015","article-title":"Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity","volume":"79","author":"Westlind-Johnsson","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib182","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40262-015-0302-2","article-title":"Pharmacokinetic aspects of vascular endothelial growth factor tyrosine kinase inhibitors","volume":"55","author":"Wulkersdorfer","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001131_bib183","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.122.001131_bib184","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/FTD.0000000000000461","article-title":"Influence of renal function on pharmacokinetics of antiepileptic drugs metabolized by CYP3A4 in a patient with renal impairment","volume":"40","author":"Yamamoto","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.122.001131_bib185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1538\/expanim.17-0048","article-title":"Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models","volume":"67","author":"Yang","year":"2018","journal-title":"Exp Anim"},{"key":"10.1124\/dmd.122.001131_bib186","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3748\/wjg.v9.i2.359","article-title":"Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases","volume":"9","author":"Yang","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.122.001131_bib187","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(24)39081-0","article-title":"Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance","volume":"294","author":"Yao","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001131_bib188","article-title":"Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient","volume":"9","author":"Ye","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.001131_bib189","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001131_bib190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/aps.2009.27","article-title":"Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects","volume":"30","author":"Zeng","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.122.001131_bib191","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1172\/JCI26283","article-title":"Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation","volume":"116","author":"Zhou","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.122.001131_bib192","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/psp4.12408","article-title":"Evaluation of the drug-drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach","volume":"8","author":"Zhou","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib193","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clinbiochem.2022.03.005","article-title":"Current status of therapeutic drug monitoring for methotrexate, imatinib, paclitaxel in China","volume":"104","author":"Zhou","year":"2022","journal-title":"Clin Biochem"},{"key":"10.1124\/dmd.122.001131_bib194","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0006-2952(93)90169-W","article-title":"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions","volume":"45","author":"Zhou","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001131_bib195","first-page":"5121","article-title":"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions","volume":"53","author":"Zhou-Pan","year":"1993","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001131_bib196","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2147\/DDDT.S237301","article-title":"Effects of apatinib on the pharmacokinetics of nifedipine and warfarin in patients with advanced solid tumors","volume":"14","author":"Zhu","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/dmd.122.001131_bib197","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0090-9556(24)02983-0","article-title":"Kinetics and regulation of cytochrome P450-mediated etoposide metabolism","volume":"32","author":"Zhuo","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.001131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:03:21Z","timestamp":1740765801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":197,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0090955624009760"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.001131","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation\/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.001131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}